We also assessed the treatment response in plasma cfDNA and interestingly, changes in BRAF V600E AF compared to baseline, indicated tumor response (decrease in AF) and progression (increase in AF) at 4 and 12 weeks after commencing therapy, respectively (Supplementary Figure 2). Here, BRAF is linked to neoplasm.